On 1 January 2020, the World Health Organisation (WHO) requested information on a reported cluster of atypical pneumonia cases in Wuhan from the Chinese authorities. On 1 March 2020, WHO made the assessment that SARS-CoV-2 could be characterized as a pandemic. The emergence of this new virus has had a major impact on the global circulation of respiratory viruses, including influenza and RSV.
The aim of the research project is to document and communicate about:
- the impact of the SARS-CoV-2 pandemic on influenza activity
- the measures to prevent and control influenza in the coming years (e.g. by vaccination).
A number of 21 contextual and geographical representative countries have been selected:
- America (4): Brazil, Canada, Mexico, USA
- Europe (8): France, Germany, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
- South Asia (4): India, Philippines, Thailand, Vietnam
- Pacific (5): Australia, China, Japan, South Korea, Taiwan
The research project consists of three components:
- establish a procedure to access and publish routine influenza (FluNet data) and SARS-CoV-2 surveillance data
- implement a testing and laboratory practices survey of National Influenza Centres to assess how SARS-CoV-2 has impacted influenza surveillance capacity
- collect influenza vaccination coverage rates in the selected countries (by risk group)
The results of this reseach project are:
- monthly publication of the FluCov epidemiological bulletin (Epi-Bulletin): an epidemiological assessment of the impact of SARS-CoV-2 on influenza activity (below)
- an abstract regarding the epidemiological impact of the SARS-CoV-2 pandemic on influenza activity, which we submit to ESCAIDE (European Scientific Conference on Applied Infectious Disease Epidemiology) in November 2021, r
- a scientific publication on the epidemiological assessment of the impact of the SARS-CoV-2 pandemic on the surveillance data (survey results) and influenza activity
- FluCov Epi-Bulletins (monthly, starting in June 2021)
- InFluNews (News letter Global Influenza Initiative GII)
Nivel project team
Participating Nivel researchers are:
The research project is funded by Sanofi Pasteur. The current research grant runs from 15 March 2021 to 14 March 2022.
Want to know more? Contact us
For more information on this project, please feel free to get in touch with the Nivel expert(s) involved. You will find them on the right, together with the (future) Nivel deliverables (publications) and other relevant content.
Paget, J. Project FluCov . From: www.nivel.nl [Last update 28-September-2021; consulted on 18-October-2021]. URL: https://www.nivel.nl/en/nivel-zorgregistraties-eerste-lijn/project-flucov-2021-2022